1. Why Did Natco Pharma Surge 13% Today?
There are several reasons why Natco Pharma’s stock has rallied by 13% today: Reason 1 – The 3 products patent for Natco had been one such case:isdigit + patent because 1/2 countries have been giving Natco products patent under S.3(d):less + Share price surged by 13%, and + It is not the first time the patent war had been used to increase share prices:less.
- Earnings or Announcement: The company may have reported positive quarterly earnings or major business developments like new product approvals or collaborations.
- Analyst Upgrades: The stock report might be based on the last few analyst upgrades who have added the stock to the growing list of recommendations and price targets.
- Market Sentiment: General market trend/sector sentiment or any other factor can influence the stock price as well.
For a detailed breakdown of the stock’s performance, refer to the Trendlyne research reports.
2. Fundamental Analysis
- Market Capitalisation: ₹14,776.6 crore.
- P/E Ratio (TTM): 7.9 Below industry average and a value which shows the stock is undervalued.
- PEG Ratio (TTM): 0.2, indicating an undervalued earnings scenario compared to its market value.
- Price-to-Book Ratio: 2.5 — The value compares favorably to the industry average, implying a relatively fair valuation.
- Beta (1 Year): 0.8, demonstrating low volatility versus the broader market.
- Recent Performance: The stock has trailed its industry’s average over the past month by 31 percentage points.
For the latest available financial information, refer to Trendlyne’s Natco Pharma page.
3. Technical Analysis
I don’t have enough chart data from the sources you gave me, but here are some technical indicators on the stock that may guide you in the direction you want. These are used to watch the market for reversals or continuation of trends.
4. Value Analysis
In view of the low P/E and PEG multiples, Natco Pharma looks undervalued in terms of earnings growth potential. This may be a value play especially if the company can continue to perform well financially and grow.AFWay user who had invested in the company-led by the co-founder of Men’s Warehouse, Joe Arriola-recently shared some highlights from the Q1 conference call:ActivityIndicatorView presents another form of private equity “protection” for shareholders.
5. Promoter’s Investment Activity
- Promoter Holding : 49.62% as of Dec 2024.
- Neutral: Steady promoter holding suggesting confidence in the company’s long term prospects.
For shareholding patterns, refer to Trendlyne Shareholding Pattern.
6. FII and DII Activity
- FII/FPI holding: FII/FPI holding increased from 17.51% to 17.94% in Dec 2024 qtr
- FII/FPI have increased holdings from 377 to 435 in Dec 2018 qtr.
- DII Holdings: Down from 6.8% to 5.6%, due to decrease in domestic institutional holdings.
Find out more about institutional holdings via Trendlyne’s Shareholding Pattern.
7. Broker Views
- ICICI Direct: Maintain Buy| Target: ₹1,675 | Upside: 103%
- Average Target Price: ₹1,593.75, according to consensus of four brokers
For latest broker research reports and other reports, visit Trendlyne’s Natco Pharma page
You can check the real-time quote of Natco Pharma on NSE’s website or few other financial websites like Moneycontrol etc.
If you want more information or details, just let me know!
